|Bid||13.93 x 800|
|Ask||13.95 x 800|
|Day's range||13.84 - 14.35|
|52-week range||11.98 - 37.75|
|Beta (5Y monthly)||1.53|
|PE ratio (TTM)||N/A|
|Earnings date||22-Apr-2020 - 26-Apr-2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||21.17|
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alkermes (ALKS) delivered earnings and revenue surprises of 25.76% and 1.14%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
We expect Alkermes (ALKS) to provide revenue updates on its proprietary marketed products and pipeline candidates when it releases fourth-quarter earnings on Feb 13.
The FDA accepts for review Alkermes' (ALKS) NDA for ALKS 3831 for the treatment of schizophrenia and bipolar I disorder and has set an action date of Nov 15, 2020.
Seattle Genetics (SGEN) submits an NDA to the FDA for tucatinib in combination with Herceptin and Xeloda seeking approval to treat locally advanced/metastatic HER2-positive breast cancer.
Alkermes (ALKS) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Alnylam (ALNY) reports positive top-line results from the phase III study on lumasiran for the treatment of primary hyperoxaluria type 1.
Mallinckrodt (MNK) initiates phase IV, multi-center, multiple-dose, open-label study to assess the effects of lead drug Acthar Gel as a therapy option in patients with severe keratitis.
Horizon Therapeutics' (HZNP) pipeline candidate, teprotumumab, gets favorable vote from DODAC of the FDA for the treatment of Thyroid Eye Disease.
As the momentum in the equity markets is expected to stay on firm-footing in 2020, these five stocks that failed to stand out in 2019 have a chance to outperform next year.
Biogen's (BIIB) gosuranemab fails to meet primary endpoint in a phase II study evaluating gosuranemab (BIIB092) in patients with progressive supranuclear palsy, a degenerative brain disorder.